COX2 overexpression is a prognostic marker for Stage III breast cancer
COX2 overexpression is a prognostic marker for Stage III breast cancer
复制标题
DOI：
10.1007/s10549-011-1521-3
复制
发表时间：
2012-02-01
影响因子：
3.8
通讯作者：
Noh, Dong-Young
中科院分区：
文献类型：
--
作者：
Kim, Hee Sung;Moon, Hyeong-Gon;Noh, Dong-Young
为了确定 (环加氧酶 2) COX2 对乳腺癌临床结果的重要性，我们分析了 687 名浸润性乳腺癌患者中 COX2 过度表达与生存之间的相关性。在 687 例浸润性乳腺癌中，有 325 例 (47.3%) 的 COX2 细胞质免疫反应性被确定为阳性。 COX2 阳性与高组织学分级、阴性雌激素受体 (ER)、高 Ki67、luminal B 和三阴性肿瘤、Bcl2 阴性和 p53 过表达显着相关。在单变量分析中，COX2 过表达导致无复发生存期 (RFS) 显着缩短 [风险比 (HR) 1.487，95% CI 1.035-2.110，P = 0.032]。多变量分析显示 COX2 过表达与总生存期 (OS) 或 RFS 之间没有显着关联。对整个患者组的 Kaplan-Meier 分析显示，与 COX2 不过度表达的患者相比，COX2 高表达患者的 RFS 显着降低（91 个月与 162 个月，P = 0.031）。按 TNM 分期进行的分层亚组分析揭示了 III 期患者的 OS 和 RFS 率存在显着差异。我们观察到，在 III 期患者 ER 阴性亚组中，COX2 过度表达与较短的 RFS 存在显着相关性。结果表明COX2过度表达是III期乳腺癌显着的不利预后因素，并为侵袭性乳腺癌治疗的COX2抑制剂组合提供了选择标准。
To determine the significance of (Cyclooxygenase 2) COX2 for clinical outcome in breast cancer, we analyzed the correlation between COX2 overexpression and survival in 687 patients with invasive breast cancer. Cytoplasmic immunoreactivity of COX2 was determined as positive in 325 of 687 (47.3%) invasive breast cancers. COX2 positivity was significantly correlated with high histologic grade, negative estrogen receptor (ER), high Ki67, luminal B and triple-negative tumors, Bcl2 negativity, and p53 overexpression. In univariate analysis, COX2 overexpression resulted in significantly shorter relapse-free survival (RFS) [hazard ratio (HR) 1.487, 95% CI 1.035-2.110, P = 0.032]. Multivariate analysis revealed no significant association between COX2 overexpression and either overall survival (OS) or RFS. Kaplan-Meier analysis of the whole patient group showed significantly reduced RFS in patients with high COX2 expression, compared to those that did not overexpress COX2 (91 vs. 162 months, P = 0.031). Stratified subgroup analysis by TNM stage disclosed marked differences in OS and RFS rates in Stage III patients. We observed a significant association of COX2 overexpression with shorter RFS in the ER-negative subgroup of Stage III patients. The results show that COX2 overexpression is a significant unfavorable prognostic factor in Stage III breast cancer, and provide selective criteria for COX2 inhibitor combinations for invasive breast cancer therapy.